Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Pediatric nephrology (Berlin, West)

• Publication date

  2025-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00467-025-07023-6PMID 41214327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes

  2025cited by this paper
• Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis

  2025cited by this paper
• Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

  2024cited by this paper
• IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis

  2024cited by this paper
• Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case–control study

  2024cited by this paper
• Efficacy and Safety of Telitacicept in IgA Nephropathy: A Retrospective, Multicenter Study

  2024cited by this paper
• Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.

  2024cited by this paper
• Immunosuppressive therapy for IgA nephropathy in children.

  2024cited by this paper
• A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.

  2024cited by this paper
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

  2024cited by this paper
• Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy

  2024cited by this paper
• Non-immunosuppressive treatment for IgA nephropathy.

  2024cited by this paper
• Efficacy and Safety of Telitacicept as an Add-On Therapy for Refractory Immunoglobulin A Nephropathy or Immunoglobulin A Vasculitis Nephropathy in Children

  2024cited by this paper
• A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.

  2023cited by this paper
• IgA Nephropathy: Beyond the Half-Century

  2023cited by this paper
• IgA nephropathy

  2023cited by this paper
• The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy

  2023cited by this paper
• Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy

  2023cited by this paper
• Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.

  2022cited by this paper
• Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

  2022cited by this paper
• Empagliflozin in Patients with Chronic Kidney Disease

  2022cited by this paper
• Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

  2022cited by this paper
• Current treatment of IgA nephropathy

  2021cited by this paper
• Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features

  2018cited by this paper
• Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT

  2018cited by this paper
• Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

  2017cited by this paper
• Pathophysiology of IgA Nephropathy.

  2017cited by this paper
• IgA Nephropathy.

  2017cited by this paper
• Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

  2016cited by this paper
• Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

  2015cited by this paper
• Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.

  2015cited by this paper
• Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features.

  2013cited by this paper
• The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity

  2013cited by this paper
• Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.

  2012cited by this paper
• The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression

  2012cited by this paper
• Long-term results of a randomized controlled trial in childhood IgA nephropathy.

  2011cited by this paper
• The pathophysiology of IgA nephropathy.

  2011cited by this paper
• Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.

  2009cited by this paper
• Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

  2009cited by this paper
• Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.

  2004cited by this paper
• [IgA nephropathy].

  1985cited by this paper

• Novel use of telitacicept in primary immune thrombocytopenia: a case report.

  2026cites this paper
• APRIL: spring forward also for IgA vasculitis nephritis in children

  2025cites this paper